Discussion With the current study, we confirm the observation made by Nauck et al. [3] in 1986 that the incretin effect is reduced in patients with type 2 diabetes, and we conclude that this ...

Depending on the blood sugar level, they promote the release of insulin from the pancreas—a mechanism known as the incretin effect. At the same time, GLP-1 inhibits the release of glucagon, a ...

This incretin effect is inhibited in those with type-2 diabetes, leading to hampered insulin production. This is why these hormones are currently therapeutic targets for treating insulin levels in ...

The incretin effect—defined as augmentation of the insulin response by gastrointestinal hormones after oral glucose intake compared with administration of glucose intravenously—is impaired in ...

Whether this effect is mediated by incretins (glucagon like peptide 1 [GLP-1] or glucose-dependent insulinotropic peptide [GIP]) is not known. The aim of this study was to show whether an equivalent ...

An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology, Diabetes Technology & Therapeutics, August 8, 2013. DOI: 10.1089/dia.2013.0177.

Session ID: 2025-06-24:7e1206e74d02b9e66ba070b0 Player Element ID: vjs_video_3 ...

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

In obese, diabetic subjects with NAFLD, the dual-pathway effect of DD01, acting through both the GLP-1 and glucagon receptor, was apparent and beneficial to these commonly co-morbid conditions.

**media [439562,439563,439564]**"The pharmacokinetic data announced today combined with the previously announced pharmacodynamic data further highlight the RaniPill's potential to serve as a novel ...